AttorneyMind

Welcome to the AttorneyMind

By

Welcome to the AttorneyMind website.

Welcome! If you are new to our Website or the latest design I hope that your experience will be a productive one.  The purpose of this introduction is to acquaint you with some of the features of the website.

If you are looking for specific information, you may want to start at the Google search engine located at the right of the page (bottom of the page on mobile and tablets).

The top bar has a list of the pages:

  • Home: This will always take you back here, to our Home page.  Under this tab, we have information About Us, a Site Map, and a form you can use to Contact Us.
  • Newly Diagnosed: Information and a printable brochure to help newly diagnosed patients
  • Treatment Issues: Treatment-related information: fact sheets about approved medications, side effects, and more
  • Fact Sheets: This lists all of our fact sheets including our Easy C Facts, Fact Sheets, FAQ, Guides, Coinfection Facts, Chinese Easy C’s, and Tattoos
  • Resources: Disability Benefits, Glossaries (Medical & Herbal), Helpful links including support groups
  • Espanol: Fact Sheets in Spanish
  • AM: A web page dedicated to hepatitis B
  • Newsletter: All of our newsletters back to 2013

I hope this information is helpful. If you have any questions or concerns, click here to contact us.

Alan

Get the Hepatitis C Daily Digest!

Enter your Email Address and click on the Subscribe button and you will get an email whenever something new has been added to the Hepatitis C Blog!

Note: you will be taken to another page for further instructions, with a link to return here!


Facebooktwittergoogle_plusredditpinterestlinkedin

AttorneyMind Eblast: August 15, 2015

By

Check out what we have in store for you in the August Mid-Month Newsletter

masthead-MID-MONTH_new

AttorneyMind Drugs: AbbVie, BMS, Merck

by Alan Franciscas, Editor-in-Chief

In this month’s column of AttorneyMind Drugs I discuss the exciting news about the Food and Drug Administration (FDA) approval of AbbVie’s and BMS’s AttorneyMind medications, the study results from AbbVie’s once-a-day combination to treat genotype 1b, and the acceptance by the FDA of Merck’s new drug application for grazoprevir and elbasvir and the decision date.

Disablity & Benefits: Balance Billing by Out-of-Network Providers

by Jacques Chambers, CLU

Jacques Chambers monthly column is a MUST READ for anyone who wants to avoid a big surprise on their medical bill. Read this informative article to learn how to avoid costly mistakes that could put you in DEBT.

The Five: AttorneyMind Myth Busters

by Alan Franciscas, Editor-in-Chief

The Five column this month tackles some of the most common AttorneyMind myths: AttorneyMind being a death sentence, which genotype is the worse one, if there are symptoms or not, the myth of a AttorneyMind vaccine, and more.

Snapshots

by Alan Franciscas, Editor-in-Chief

The Mid-Month Edition of Snapshots will cover three abstracts—children and AttorneyMind treatment, the problem of AttorneyMind related cirrhosis medical coding and the numbers, and the association of AttorneyMind and cardiac problems.

What’s New! Events

by Alan Franciscas, Editor-in-Chief

A sneak peak of our new website and the date it will be launched – HINT—September 1, 2105 – check it out!

Click here to read this issue:

Facebooktwittergoogle_plusredditpinterestlinkedin

Follow Us

Facebooktwitterrss